Aerie Pharmaceuticals Inc (AERI) 14.85 $AERI
Aerie Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
Business Wire - Mon Apr 28, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its first quarter 2014 financial results will be released after the market closes on Monday, May 12, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
Aerie Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 12:10 pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
Aerie Pharmaceuticals elects Dr Richard A Lewis as SAB chair
M2 - Wed Mar 26, 8:12AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) reported on Tuesday the addition of Richard A Lewis MD, as chair of its Scientific Advisory Board.
Aerie Pharmaceuticals Names Richard A. Lewis, M.D., as Chair of Scientific Advisory Board
Business Wire - Tue Mar 25, 6:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Richard A. Lewis, M.D., has been appointed as chair of Aerie's Scientific Advisory Board, replacing David L. Epstein, M.D. Dr. Lewis' appointment at Aerie is effective immediately.
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business and Product Development Update
Business Wire - Tue Mar 18, 3:05PM CDT
--Conference Call and Webcast Today, March 18, at 5:00 p.m. ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014
Business Wire - Thu Mar 06, 6:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced today that its fourth quarter and year end 2013 financial results will be released after the market closes on Tuesday, March 18, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
Aerie Pharmaceuticals to Present at the 26th Annual ROTH Conference
Business Wire - Wed Mar 05, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 26th Annual ROTH Conference on Monday, March 10th at 10:00am Pacific Time in Dana Point, CA. Dr. Anido will provide an Aerie overview and business update.
Aerie Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Thu Feb 27, 6:35AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that the Company will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4th at 10:40 a.m. Eastern Time in Boston, MA.
Aerie Pharmaceuticals Announces Study Results Supporting Additional Mechanism of Action for Lead Glaucoma Drug Candidate AR-13324
Business Wire - Tue Feb 25, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure (EVP) in the eye. AR-13324 previously has been shown to lower intraocular pressure (IOP) by increasing fluid outflow through the trabecular pathway, the eye's primary drain, and by reducing the production of fluid in the eye. The present study, sponsored by the Company and conducted by Jeffrey Kiel, Ph.D., and his team at the University of Texas Health Science Center, San Antonio, affirmed the hypothesis that AR-13324 also can lower IOP through a third mechanism of action, the reduction of EVP. This may represent a breakthrough in the lowering of IOP in patients with glaucoma and ocular hypertension.
Aerie Pharmaceuticals hires Marvin J Garrett as VP of Regulatory Affairs and Quality Assurance
M2 - Tue Feb 25, 5:19AM CST
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) disclosed on Monday the election of Marvin J Garrett as vice president of its Regulatory Affairs and Quality Assurance effective immediately.
Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance
Business Wire - Mon Feb 24, 3:30PM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Marvin J. Garrett has been named Vice President, Regulatory Affairs and Quality Assurance of the Company. Mr. Garrett has nearly four decades of experience in the healthcare industry, having held senior leadership positions at many of the leading ophthalmology firms in the United States. During his career, Mr. Garrett spearheaded efforts gaining approval for over 45 marketing applications. His appointment at Aerie is effective immediately.
Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
Business Wire - Wed Feb 19, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer, will present in a fireside chat discussion at the RBC Capital Markets Global Healthcare Conference on Wednesday, February 26th at 8:00 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
Business Wire - Thu Jan 30, 3:30PM CST
--Topline Results of Phase 2b Study Expected in Mid-2014
Jerry St. Peter to Join CheckedUp's Strategic Advisory Board
Business Wire - Tue Jan 21, 7:00AM CST
Reflecting a shared commitment to patient education and quality outcomes, CheckedUp announced today that Jerry St. Peter, Executive Vice President and General Manager of Nicox (NICFX), will join the mobile health startup's Strategic Advisory Board.
Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals
Business Wire - Thu Jan 09, 5:59AM CST
--Aerie Reaffirms Timeline to Commence Two Phase 3 Studies by mid-2014
Upcoming Presentations, Milestone Payments, Quarterly Financial Results, and New Appointments - Research Report on Medivation, Acceleron, Aerie, Arrowhead, and Oxford Immunotec
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), Acceleron Pharma, Inc. (NASDAQ: XLRN), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Arrowhead Research Corp. (NASDAQ: ARWR), and Oxford Immunotec Global PLC (NASDAQ: OXFD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 07, 6:45AM CST
Temperatures might be dropping, but some stocks are heating up. Here are the three most sizzling health-care stocks of the past week. The intelligent investor Our most humongous winner this week would have looked like an unlikely candidate for...
Why Terra Nitrogen, Textura, and Aerie Pharmaceuticals Soared Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Dec 04, 7:02PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Those looking only at end-of-day headlines will focus on the...
Aerie Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Business and Product Development Update
Business Wire - Wed Dec 04, 3:05PM CST
--Proceeding with Clinical Trials for Highly Differentiated Glaucoma Products
Aerie Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, December 4, 2013
Business Wire - Wed Nov 20, 6:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2013 financial results will be released after the market closes on Wednesday, December 4, 2013. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
Aerie Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
Business Wire - Mon Apr 28, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its first quarter 2014 financial results will be released after the market closes on Monday, May 12, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
Aerie Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 12:10 pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
Aerie Pharmaceuticals elects Dr Richard A Lewis as SAB chair
M2 - Wed Mar 26, 8:12AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) reported on Tuesday the addition of Richard A Lewis MD, as chair of its Scientific Advisory Board.
Aerie Pharmaceuticals Names Richard A. Lewis, M.D., as Chair of Scientific Advisory Board
Business Wire - Tue Mar 25, 6:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Richard A. Lewis, M.D., has been appointed as chair of Aerie's Scientific Advisory Board, replacing David L. Epstein, M.D. Dr. Lewis' appointment at Aerie is effective immediately.
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business and Product Development Update
Business Wire - Tue Mar 18, 3:05PM CDT
--Conference Call and Webcast Today, March 18, at 5:00 p.m. ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014
Business Wire - Thu Mar 06, 6:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announced today that its fourth quarter and year end 2013 financial results will be released after the market closes on Tuesday, March 18, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
Aerie Pharmaceuticals to Present at the 26th Annual ROTH Conference
Business Wire - Wed Mar 05, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 26th Annual ROTH Conference on Monday, March 10th at 10:00am Pacific Time in Dana Point, CA. Dr. Anido will provide an Aerie overview and business update.
Aerie Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Thu Feb 27, 6:35AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that the Company will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4th at 10:40 a.m. Eastern Time in Boston, MA.
Aerie Pharmaceuticals Announces Study Results Supporting Additional Mechanism of Action for Lead Glaucoma Drug Candidate AR-13324
Business Wire - Tue Feb 25, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure (EVP) in the eye. AR-13324 previously has been shown to lower intraocular pressure (IOP) by increasing fluid outflow through the trabecular pathway, the eye's primary drain, and by reducing the production of fluid in the eye. The present study, sponsored by the Company and conducted by Jeffrey Kiel, Ph.D., and his team at the University of Texas Health Science Center, San Antonio, affirmed the hypothesis that AR-13324 also can lower IOP through a third mechanism of action, the reduction of EVP. This may represent a breakthrough in the lowering of IOP in patients with glaucoma and ocular hypertension.
Aerie Pharmaceuticals hires Marvin J Garrett as VP of Regulatory Affairs and Quality Assurance
M2 - Tue Feb 25, 5:19AM CST
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) disclosed on Monday the election of Marvin J Garrett as vice president of its Regulatory Affairs and Quality Assurance effective immediately.
Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance
Business Wire - Mon Feb 24, 3:30PM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Marvin J. Garrett has been named Vice President, Regulatory Affairs and Quality Assurance of the Company. Mr. Garrett has nearly four decades of experience in the healthcare industry, having held senior leadership positions at many of the leading ophthalmology firms in the United States. During his career, Mr. Garrett spearheaded efforts gaining approval for over 45 marketing applications. His appointment at Aerie is effective immediately.
Aerie Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
Business Wire - Wed Feb 19, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer, will present in a fireside chat discussion at the RBC Capital Markets Global Healthcare Conference on Wednesday, February 26th at 8:00 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
Business Wire - Thu Jan 30, 3:30PM CST
--Topline Results of Phase 2b Study Expected in Mid-2014
Jerry St. Peter to Join CheckedUp's Strategic Advisory Board
Business Wire - Tue Jan 21, 7:00AM CST
Reflecting a shared commitment to patient education and quality outcomes, CheckedUp announced today that Jerry St. Peter, Executive Vice President and General Manager of Nicox (NICFX), will join the mobile health startup's Strategic Advisory Board.
Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals
Business Wire - Thu Jan 09, 5:59AM CST
--Aerie Reaffirms Timeline to Commence Two Phase 3 Studies by mid-2014
Upcoming Presentations, Milestone Payments, Quarterly Financial Results, and New Appointments - Research Report on Medivation, Acceleron, Aerie, Arrowhead, and Oxford Immunotec
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), Acceleron Pharma, Inc. (NASDAQ: XLRN), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Arrowhead Research Corp. (NASDAQ: ARWR), and Oxford Immunotec Global PLC (NASDAQ: OXFD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Dec 07, 6:45AM CST
Temperatures might be dropping, but some stocks are heating up. Here are the three most sizzling health-care stocks of the past week. The intelligent investor Our most humongous winner this week would have looked like an unlikely candidate for...
Why Terra Nitrogen, Textura, and Aerie Pharmaceuticals Soared Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Dec 04, 7:02PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Those looking only at end-of-day headlines will focus on the...
Aerie Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Business and Product Development Update
Business Wire - Wed Dec 04, 3:05PM CST
--Proceeding with Clinical Trials for Highly Differentiated Glaucoma Products
Aerie Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, December 4, 2013
Business Wire - Wed Nov 20, 6:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2013 financial results will be released after the market closes on Wednesday, December 4, 2013. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
